Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Monoclonal Antibody Blocks B-Cell Receptor and Eases Leukemia Burden in Mouse Model

By BiotechDaily International staff writers
Posted on 26 May 2014
Blocking the B-cell-activating factor receptor (BAFF-R) on leukemia cells has been suggested as a new approach for treating an acute, chemotherapy-resistant form of childhood leukemia.

Acute lymphoblastic leukemia (ALL) is characterized by an excessive amount of white blood cell precursors (B-cell lymphoblasts) in the blood and bone marrow. B-cell lineage ALL (pre-B ALL) accounts for 80% to 85% of childhood ALL.

BAFF-R is encoded in humans by the TNFRSF13C (tumor necrosis factor receptor superfamily member 13C) gene. BAFF enhances B-cell survival in vitro and is a regulator of the peripheral B-cell population. Overexpression of BAFF in mice results in mature B-cell hyperplasia and symptoms of systemic lupus erythematosus (SLE). Also, some SLE patients have increased levels of BAFF in their serum. Therefore, it has been proposed that abnormally high levels of BAFF may contribute to the pathogenesis of autoimmune diseases by enhancing the survival of autoreactive B cells. The protein encoded by the TNFRSF13C gene is a receptor for BAFF and is a type III transmembrane protein containing a single extracellular cysteine-rich domain.

It is thought that BAFF-R is the principal receptor required for BAFF-mediated mature B-cell survival. Since BAFF-R is expressed on precursor pre-B ALL cells but not on their pre-B normal counterparts, selective killing of ALL cells is possible by targeting this receptor.

Investigators at the University of Southern California (USA) tested a novel humanized anti–BAFF-R monoclonal antibody in a study carried out on leukemia cell cultures and in an immunodeficient mouse transplant model.

They reported in the May 13, 2014, online edition of the journal Molecular Cancer Therapeutics that the antibodies significantly stimulated natural killer cell-mediated killing of different human patient-derived ALL cells. Moreover, incubation of such ALL cells with these antibodies stimulated phagocytosis by macrophages. When this was tested in the immunodeficient transplant model, mice that were treated with the antibody had a significantly decreased leukemia burden in bone marrow and spleen.

"We have now demonstrated that BAFF-R is a strong potential therapeutic target for treating chemotherapy-resistant leukemia cells, without damaging healthy cells," said senior author Dr. Nora Heisterkamp, professor of research, pediatrics, and pathology at the University of Southern California. "We found that human pre-B ALL cells could be even further reduced when the anti-BAFF-R antibody was combined with chemotherapy or another therapeutic agent. We are looking at a potential one, two punch."

Related Links:

University of Southern California



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent treated with the HDL peptide (right). Note the much narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with 4F peptide treatment (Photo courtesy of UCLA - University of California, Los Angeles).

Apolipoprotein A-1 Mimetic Peptide Reverses Pulmonary Hypertension in Rodent Models

A small peptide that mimics the activity of apolipoprotein A-1 (apo A-1), the main protein component of the high density lipoproteins (HDL), counteracted the effects of oxidized lipids and alleviated symptoms... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel

Important Immune Cell Regulators’ Response Identified

A new strategy could help accelerate laboratory research and the development of potential therapeutics, including vaccines. The technology may also be used to identify the genes that underlie tumor cell development. There are approximately 40,000 genes in each of the body’s cells, but functions for only approximately... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.